Ces radiol. 2008, 62(1):60-65

Detection of the colorectal carcinoma liver metastases with magnetic resonance after intravenous application of hepatocellular contrast agent (Gd-EOB-DTPA), comparison with the intraoperative ultrasoundOriginal article

Jiří Ferda1, Hynek Mírka1, Jan Kastner1, Kristýna Ohlídalová1, Eva Ferdova1, Renata Vondráková1, Boris Kreuzberg1, Vladislav Třeška2, Tomáš Skalický2, Alan Sutnar2
1 Radiodiagnostická klinika LF UK a FN, Plzeň
2 Chirurgická klinika LF UK a FN, Plzeň

Aim: The aim of our prospective study was to evaluate the accuracy of magnetic resonance imaging (MRI) with intravenous application of hepatocellular contrast agent (gadoxetic acid, Gd-EOB-DTPA) in the detection of liver metastases before surgery.

Method: Thirty consecutive patients (mean age 60.7 years; range 36-79) were enrolled into study. All examinations were performed with intravenous application of hepatospecific contrast agent (gadoxetic acid) using 1.5 T magnetic resonance system. The imaging protocol consisted of T1-weighted spoiled gradient echo sequences in the arterial, portal and interstitial phases, followed by delayed hepatospecific phase at 10 and 20 minutes after contrast material administration. T2-weighted sequences were also used but were not included in the comparison. All patients underwent open surgery including intraoperative ultrasound (IOUS) performed with dedicated T-shape US probe within 24 hours. The results were compared with MRI findings.

Results: A total of 64 lesions (49 metastases) were found by IOUS. 46 metastases were depicted by MRI (sensitivity 94%). Fifteen non-metastatic lesions were found on IOUS, two of them (small haemangiomas) were misinterpreted as metastases by MRI (specificity 87%).

Conclusion: The results of the study show excellent clinical value of MRI with intravenous application of gadoxetic acid in assessment of liver involvement in subjects with metastasizing colorectal carcinoma.

Keywords: gadoxetic acid, Gd-EOB-DTPA, hepatobiliary contrast agents, liver metastases, colorectal carcinoma, magnetic resonance imaging, intraoperative ultrasound
Grants and funding:

Práce byla podpořena výzkumnými projekty IGA MZCR NR/8301-3 a MSM 0021620819.

Accepted: September 3, 2007; Published: March 1, 2008  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Ferda J, Mírka H, Kastner J, Ohlídalová K, Ferdova E, Vondráková R, et al.. Detection of the colorectal carcinoma liver metastases with magnetic resonance after intravenous application of hepatocellular contrast agent (Gd-EOB-DTPA), comparison with the intraoperative ultrasound. Ces radiol. 2008;62(1):60-65.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Saini S, Stark DD, Hahn PF, Wittenberg J, Brady TJ, Ferrucci JT Jr. Ferrite particles: a superparamagnetic MR contrast agent for the reticuloendothelial system. Radiology 1987; 162: 211-216. Go to original source... Go to PubMed...
    2. Jung G, Heindel W, Krahe T, Kugel H, Walter C, Fischbach R, Klaus H, Lackner K. Influence of the hepatobiliary contrast agent mangafodipir trisodium (MN-DPDP) on the imaging properties of abdominal organs. Magn Reson Imaging 1998; 16(8): 925-931. Go to original source... Go to PubMed...
    3. Bollow M, Taupitz M, Hamm B, Staks T, Wolf KJ, Weinmann HJ. Gadoliniumethoxybenzyl-DTPA as a hepatobiliary contrast agent for use in MR cholangiography: results of an in vivo phase-I clinical evaluation. Eur Radiol 1997; 7: 126-132. Go to original source... Go to PubMed...
    4. Schmitz SA, Wagner S, Schuhmann-Giampieri G, Krause W, Wolf KJ. A prototype liver-specific contrast medium for CT: preclinical evaluation of gadoxetic acid disodium, or Gd-EOB-DTPA. Radiology. 1997; 202(2): 407-412. Go to original source... Go to PubMed...
    5. Huppertz A, Balzer T, Blakeborough A, Breuer J, Giovagnoni A, Heinz-Peer G, Laniado M, Manfredi RM, Mathieu DG, Mueller D, Reimer P, Robinson PJ, Strotzer M, Taupitz M, Vogl TJ. European EOB Study Group. Improved detection of focal liver lesions at MR imaging: multicenter comparison of gadoxetic acid-enhanced MR images with intraoperative findings. Radiology 2004; 230: 266-275. Go to original source... Go to PubMed...
    6. Huppertz A, Haraida S, Kraus A, Zech CJ, Scheidler J, Breuer J, Helmberger TK, Reiser MF. Enhancement of focal liver lesions at gadoxetic acid-enhanced MR maging: correlation with histopathologic findings and spiral CT-initial observations. Radiology 2005; 234: 468-478. Go to original source... Go to PubMed...
    7. Patel NA, Roh MS. Utility of intraoperative liver ultrasound. Surg Clin North Am 2004; 84: 513-524. Review. Go to original source... Go to PubMed...
    8. Takigawa Y, Sugawara Y, Yamamoto J, Shimada K, Yamasaki S, Kosuge T, Makuuchi M. New lesions detected by intraoperative ultrasound during liver resection for hepatocellular carcinoma. Ultrasound Med Biol 2001; 27: 151-156. Go to original source... Go to PubMed...
    9. Schmitt-Willich H, Brehm M, Ewers CL, Michl G, Muller-Fahrnow A, Petrov O, Platzek J, Raduchel B, Sulzle D. Synthesis and Physicochemical Characterization of a New Gadolinium Chelate: The Liver-Specific Magnetic Resonance Imaging Contrast Agent Gd-EOB-DTPA. Inorg Chem 1999 Mar 22; 38: 1134-1144. Go to original source... Go to PubMed...
    10. Žižka J, Klzo L, Ferda J, Mrklovský M, Bukač J. Dynamic and delayed contrast enhancement in upper abdominal MRI studies: comparison of gadoxetic acid and gadobutrol. Eur J Radiol 2007; 62: 186-191. Go to original source... Go to PubMed...
    11. Reimer P, Schneider G, Schima W. Hepatobiliary contrast agents for contrast-enhanced MRI of the liver: properties, clinical development and applications. Eur Radiol 2004; 14: 559-578. Go to original source... Go to PubMed...
    12. Zech CJ, Herrmann KA, Reiser MF, Schoenberg SO. MR Imaging in Patients with suspected Liver Metastases: Value of Liver-specific Contrast Agent Gd-EOB-DTPA. Magn Reson Med Sci 2007; 6: 43-52. Go to original source... Go to PubMed...
    13. Petersein J, Saini S, Weissleder R. Liver. II: Iron oxide-based reticuloendothelial contrast agents for MR imaging. Clinical review. Magn Reson Imaging Clin N Am 1996; 4: 53-60. Go to original source...
    14. Jung G, Breuer J, Poll LW, Koch JA, Balzer T, Chang S, Modder U. Imaging characteristics of hepatocellular carcinoma using the hepatobiliary contrast agent Gd-EOB-DTPA. Acta Radiol 2006; 47: 15-23. Go to original source... Go to PubMed...
    15. Bluemke DA, Sahani D, Amendola M, et al. Efficacy and safety of MR imaging with liver specific contrast agent: US multicenter phase III study. Radiology 2005; 237: 89-98. Go to original source... Go to PubMed...
    16. Kim YK, Lee JM, Kim CS, Cchung GH, Kim CY, Kim IH. Detection of liver metastases: comparison of gadobenat imeglumine-enhanced three-dimensional dynamic phases and one-hour delayed phase MRI imaging versus superparamagnetic iron oxide-enhanced MR imaging. Eur Radiol 2005; 15: 220-228. Go to original source... Go to PubMed...
    17. Del Frate C, Bazzocchi M, Mortele KJ, et al. Detection of liver metastases: gadobenat dimeglumine-enhanced and ferrumoxides-enhanced MR imaging examinations. Radiology 2002; 225: 766-772. Go to original source... Go to PubMed...

    This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.


    Return to the content